An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

NCT05102409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Xiidra® (5% lifitegrast ophthalmic solution)

Sponsor

Aldeyra Therapeutics, Inc.